Could the anti-modified protein antibody concept help better define seronegative rheumatoid arthritis?
Authors:
- 25 February 2025
- journal article
- Published by Elsevier in Joint Bone Spine
- Vol. 92 (5) , 105869
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- 2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritisJoint Bone Spine, 2024
- Risk of cardiovascular comorbidities before and after the onset of rheumatic diseasesSeminars in Arthritis and Rheumatism, 2024
- A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung DiseaseArthritis & Rheumatology, 2022
- The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesRheumatology, 2020
- Comprehensive Profiling of the Rheumatoid Arthritis Antibody RepertoireArthritis & Rheumatology, 2019
- Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritisRheumatology, 2018
- Association of the Presence of Anti–Carbamylated Protein Antibodies in Early Arthritis With a Poorer Clinical and Radiologic OutcomeArthritis & Rheumatology, 2017
- Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteriaAnnals of the Rheumatic Diseases, 2017
- Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodiesAnnals of the Rheumatic Diseases, 2014
- Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damageProceedings of the National Academy of Sciences, 2011